Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

Gloria N. Mattiuzzi, Jorge Cortes, Gladys Alvarado, Srdan Verstovsek, Charles Koller, Sherry Pierce, Deborah Blamble, Stefan Faderl, Lianchun Xiao, Mike Hernandez, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Purpose: To compare the efficacy and safety of voriconazole with itraconazole as prophylaxis in leukemia patients. Methods: Open-label, randomized study. Patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome undergoing induction chemotherapy or first salvage were eligible. Patients received voriconazole (400 mg intravenous (IV) every 12 h for two doses, followed by 300 mg BID) or itraconazole (200 mg IV twice daily for 2 days, followed by 200 mg IV daily). Results: A total of 127 patients were enrolled. Four were excluded because they did not receive study drug (n = 3) or received two antifungal agents during the first week on study (n = 1), leaving 123 patients for analysis. None of the 71 patients receiving voriconazole developed proven or probable invasive fungal infection, compared to two (4%) of the 52 patients receiving itraconazole (P = 0.17). Drug discontinuation because of adverse events occurred in 15 patients (21%) receiving voriconazole and six (11%) receiving itraconazole (P = 0.23). Conclusions: Voriconazole is a good alternative for prophylaxis in patients with leukemia. Elevated baseline bilirubin levels were associated with a higher risk of side effects in patients receiving IV voriconazole or IV itraconazole. Monitoring of liver function and drug levels should be considered for some patients.

Original languageEnglish (US)
Pages (from-to)19-26
Number of pages8
JournalSupportive Care in Cancer
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Itraconazole
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Safety
Leukemia
Voriconazole
Pharmaceutical Preparations
Induction Chemotherapy
Antifungal Agents
Bilirubin

Keywords

  • Fungal infection
  • Itraconazole
  • Leukemia
  • Prophylaxis
  • Voriconazole

ASJC Scopus subject areas

  • Oncology

Cite this

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. / Mattiuzzi, Gloria N.; Cortes, Jorge; Alvarado, Gladys; Verstovsek, Srdan; Koller, Charles; Pierce, Sherry; Blamble, Deborah; Faderl, Stefan; Xiao, Lianchun; Hernandez, Mike; Kantarjian, Hagop.

In: Supportive Care in Cancer, Vol. 19, No. 1, 01.01.2011, p. 19-26.

Research output: Contribution to journalArticle

Mattiuzzi, Gloria N. ; Cortes, Jorge ; Alvarado, Gladys ; Verstovsek, Srdan ; Koller, Charles ; Pierce, Sherry ; Blamble, Deborah ; Faderl, Stefan ; Xiao, Lianchun ; Hernandez, Mike ; Kantarjian, Hagop. / Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. In: Supportive Care in Cancer. 2011 ; Vol. 19, No. 1. pp. 19-26.
@article{f32b41805b594926aefb3b2805552ba8,
title = "Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome",
abstract = "Purpose: To compare the efficacy and safety of voriconazole with itraconazole as prophylaxis in leukemia patients. Methods: Open-label, randomized study. Patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome undergoing induction chemotherapy or first salvage were eligible. Patients received voriconazole (400 mg intravenous (IV) every 12 h for two doses, followed by 300 mg BID) or itraconazole (200 mg IV twice daily for 2 days, followed by 200 mg IV daily). Results: A total of 127 patients were enrolled. Four were excluded because they did not receive study drug (n = 3) or received two antifungal agents during the first week on study (n = 1), leaving 123 patients for analysis. None of the 71 patients receiving voriconazole developed proven or probable invasive fungal infection, compared to two (4{\%}) of the 52 patients receiving itraconazole (P = 0.17). Drug discontinuation because of adverse events occurred in 15 patients (21{\%}) receiving voriconazole and six (11{\%}) receiving itraconazole (P = 0.23). Conclusions: Voriconazole is a good alternative for prophylaxis in patients with leukemia. Elevated baseline bilirubin levels were associated with a higher risk of side effects in patients receiving IV voriconazole or IV itraconazole. Monitoring of liver function and drug levels should be considered for some patients.",
keywords = "Fungal infection, Itraconazole, Leukemia, Prophylaxis, Voriconazole",
author = "Mattiuzzi, {Gloria N.} and Jorge Cortes and Gladys Alvarado and Srdan Verstovsek and Charles Koller and Sherry Pierce and Deborah Blamble and Stefan Faderl and Lianchun Xiao and Mike Hernandez and Hagop Kantarjian",
year = "2011",
month = "1",
day = "1",
doi = "10.1007/s00520-009-0783-3",
language = "English (US)",
volume = "19",
pages = "19--26",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

AU - Mattiuzzi, Gloria N.

AU - Cortes, Jorge

AU - Alvarado, Gladys

AU - Verstovsek, Srdan

AU - Koller, Charles

AU - Pierce, Sherry

AU - Blamble, Deborah

AU - Faderl, Stefan

AU - Xiao, Lianchun

AU - Hernandez, Mike

AU - Kantarjian, Hagop

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Purpose: To compare the efficacy and safety of voriconazole with itraconazole as prophylaxis in leukemia patients. Methods: Open-label, randomized study. Patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome undergoing induction chemotherapy or first salvage were eligible. Patients received voriconazole (400 mg intravenous (IV) every 12 h for two doses, followed by 300 mg BID) or itraconazole (200 mg IV twice daily for 2 days, followed by 200 mg IV daily). Results: A total of 127 patients were enrolled. Four were excluded because they did not receive study drug (n = 3) or received two antifungal agents during the first week on study (n = 1), leaving 123 patients for analysis. None of the 71 patients receiving voriconazole developed proven or probable invasive fungal infection, compared to two (4%) of the 52 patients receiving itraconazole (P = 0.17). Drug discontinuation because of adverse events occurred in 15 patients (21%) receiving voriconazole and six (11%) receiving itraconazole (P = 0.23). Conclusions: Voriconazole is a good alternative for prophylaxis in patients with leukemia. Elevated baseline bilirubin levels were associated with a higher risk of side effects in patients receiving IV voriconazole or IV itraconazole. Monitoring of liver function and drug levels should be considered for some patients.

AB - Purpose: To compare the efficacy and safety of voriconazole with itraconazole as prophylaxis in leukemia patients. Methods: Open-label, randomized study. Patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome undergoing induction chemotherapy or first salvage were eligible. Patients received voriconazole (400 mg intravenous (IV) every 12 h for two doses, followed by 300 mg BID) or itraconazole (200 mg IV twice daily for 2 days, followed by 200 mg IV daily). Results: A total of 127 patients were enrolled. Four were excluded because they did not receive study drug (n = 3) or received two antifungal agents during the first week on study (n = 1), leaving 123 patients for analysis. None of the 71 patients receiving voriconazole developed proven or probable invasive fungal infection, compared to two (4%) of the 52 patients receiving itraconazole (P = 0.17). Drug discontinuation because of adverse events occurred in 15 patients (21%) receiving voriconazole and six (11%) receiving itraconazole (P = 0.23). Conclusions: Voriconazole is a good alternative for prophylaxis in patients with leukemia. Elevated baseline bilirubin levels were associated with a higher risk of side effects in patients receiving IV voriconazole or IV itraconazole. Monitoring of liver function and drug levels should be considered for some patients.

KW - Fungal infection

KW - Itraconazole

KW - Leukemia

KW - Prophylaxis

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=78651490152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651490152&partnerID=8YFLogxK

U2 - 10.1007/s00520-009-0783-3

DO - 10.1007/s00520-009-0783-3

M3 - Article

C2 - 19956980

AN - SCOPUS:78651490152

VL - 19

SP - 19

EP - 26

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 1

ER -